BiotechTube

recombinant human erythropoietin + recombinant human erythropoietin placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chemotherapy Induced Anemia

Conditions

Chemotherapy Induced Anemia

Trial Timeline

Dec 1, 2003 → Aug 1, 2005

NCT ID
NCT00144482

About recombinant human erythropoietin + recombinant human erythropoietin placebo

recombinant human erythropoietin + recombinant human erythropoietin placebo is a phase 3 stage product being developed by Chugai Pharmaceutical for Chemotherapy Induced Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00144482. Target conditions include Chemotherapy Induced Anemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00144482Phase 3Completed

Competing Products

20 competing products in Chemotherapy Induced Anemia

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
36
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
77
RoxadustatAstellas PharmaPhase 2
52
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
52
olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
77
Sancuso + IV granisetronKyowa KirinPhase 1
33
granisetron transdermal system + Granisetron IVKyowa KirinPhase 1
33
palonesetronEisaiPhase 2
52
GranisetronKyowa KirinPhase 3
77
Sancuso + IV granisetronKyowa KirinPhase 1
33
ONO-7746Ono PharmaceuticalPhase 1
33
ONO-2910 + PlaceboOno PharmaceuticalPhase 2
52
PROCRIT 40,000 IU QW + PlaceboJohnson & JohnsonPhase 2
52
Epoetin alfaJohnson & JohnsonPhase 2
52
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 2
52
Hetrombopag + Hetrombopag plus Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + Matching placeboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
77
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
77

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77